Welcome to our dedicated page for Coherus Oncology SEC filings (Ticker: CHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Coherus Oncology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Coherus Oncology's regulatory disclosures and financial reporting.
Coherus Oncology, Inc. ownership update: Thomas A. Satterfield, Jr. reports beneficial ownership of 6,930,000 shares, equal to 4.6% of the company's common stock. The filing cites 149,889,902 shares outstanding as of February 28, 2026 per the issuer's Form 10-K. The reported holdings combine sole and shared voting/dispositive power and include shares held jointly, by related entities (Tomsat Investment & Trading Co., Inc.; Caldwell Mill Opportunity Fund; A.G. Family L.P.) and multiple limited powers of attorney for other holders.
Coherus Oncology, Inc. amendment to a Schedule 13G/A reports that BlackRock, Inc. beneficially owned 7,337,261 shares of Common Stock, representing 4.9% of the class. The filing lists sole voting power of 7,232,734 shares and sole dispositive power of 7,337,261. The form is signed by a BlackRock Managing Director on 04/27/2026.
Coherus Oncology, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on director elections, auditor ratification, executive pay, a one-time stock option repricing and a larger equity incentive pool. Holders of 154,217,609 common shares as of April 16, 2026 may vote online or by proxy.
Stockholders will elect two Class III directors, ratify Ernst & Young LLP as independent auditor for 2026, and cast an advisory “say‑on‑pay” vote on named executive officer compensation. They are also being asked to approve reducing the exercise price and extending the term of 9,540,140 underwater employee and consultant options, and to add 7,700,000 shares to the Amended and Restated 2014 Equity Incentive Award Plan.
The board, which is majority independent and organized into audit, compensation, and nominating/governance committees, recommends voting “FOR” all five proposals, including the equity plan amendment intended to preserve stock‑based incentives as a core element of compensation and retention.
Coherus Oncology, Inc. filed preliminary proxy materials for its virtual 2026 Annual Meeting to be held on May 27, 2026. The Board asks stockholders to vote on election of directors, ratification of Ernst & Young as auditor, a non-binding say-on-pay, a one-time repricing of certain employee and consultant stock options covering 9,540,140 shares with exercise prices from $5.44 to $30.98, and a proposed 7,700,000-share increase to the 2014 Equity Incentive Award Plan reserve.
The repricing would reset Eligible Options to the closing price on the meeting date and extend option terms by ten years, but would restore original exercise prices if options are exercised or service terminates before May 27, 2027. The Board recommends a vote "FOR" all proposals.
Coherus Oncology Inc — The Vanguard Group filed Amendment No. 5 to Schedule 13G/A reporting 0 shares beneficially owned of Coherus Oncology common stock, representing 0% of the class. The filing includes a disclosure that Vanguard underwent an internal realignment on January 12, 2026 leading to disaggregated reporting. The form is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026.
Coherus Oncology, Inc. describes a strategic shift to become a fully integrated commercial-stage oncology company centered on its PD‑1 inhibitor LOQTORZI for nasopharyngeal carcinoma and a focused immuno-oncology pipeline.
LOQTORZI is FDA‑approved in the United States for first‑line metastatic or recurrent locally advanced nasopharyngeal carcinoma in combination with cisplatin and gemcitabine, and as monotherapy after platinum-based chemotherapy. The company estimates up to 2,000 recurrent or metastatic NPC patients in the United States are eligible, representing a $250 million market opportunity.
Coherus highlights mid‑stage clinical candidates casdozokitug (anti‑IL‑27) and tagmokitug (anti‑CCR8), both intended for combination use with LOQTORZI and partners’ agents across liver, head and neck, colorectal and other cancers. It reports multiple collaborations and licenses, including Junshi Biosciences, Apotex, Janssen, Adimab and Vaccinex.
The company notes completion of the divestiture of its UDENYCA biosimilar franchise in April 2025, reinforcing its oncology focus. As of June 30 2025, aggregate market value of common stock held by non‑affiliates was approximately $81.9 million, and shares outstanding were 149,889,902 as of February 28 2026.
Coherus Oncology, Inc. reported 2025 results showing strong product growth alongside continued losses from continuing operations. LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024, helping lift total net revenue from continuing operations to $42.2 million from $26.4 million.
The company reduced secured and convertible debt by about 90% over 2024–2025, from $480 million to $38.8 million, and ended 2025 with $172.1 million in cash, cash equivalents and marketable securities. Research and development spending from continuing operations increased to $108.9 million, reflecting investment in pipeline candidates casdozokitug and tagmokitug, while selling, general and administrative expenses declined to $100.6 million.
Net loss from continuing operations for 2025 narrowed to $183.1 million, or $(1.56) per diluted share, from $215.4 million, or $(1.88) per share, in 2024. Including large gains from discontinued operations, Coherus reported full-year net income of $168.0 million for 2025 compared with $28.5 million in 2024.
Coherus Oncology, Inc. completed an underwritten public offering of its common stock. The company sold 28,600,000 shares at a price to the public of $1.75 per share, with underwriters purchasing at $1.645 per share, generating approximately $47.0 million in net proceeds before expenses.
The underwriters also received a 30-day option to buy up to an additional 4,290,000 shares to cover any over-allotments. Coherus, its directors, executive officers and certain affiliated stockholders agreed to a 60-day lock-up on additional common stock sales, subject to specified exceptions.
Coherus Oncology, Inc. is conducting a primary offering of 28,600,000 shares of common stock at $1.75 per share, with expected net proceeds of about $46.5 million, plus a 30‑day option for underwriters to buy up to 4,290,000 additional shares.
The company plans to use the funds to support commercialization of LOQTORZI, advance clinical development of its oncology pipeline, and for working capital and general corporate purposes. Preliminary 2025 results show estimated net revenue of $42.2 million, up from $26.4 million in 2024, driven largely by $40.8 million of LOQTORZI sales.
Cash, cash equivalents and marketable securities are estimated at $172.1 million as of December 31, 2025, and Coherus expects this liquidity to fund operations through the end of 2026, while still recording a loss from continuing operations for the fourth quarter of 2025.